Dihydrotestosterone (DHT) is the most potent naturally occurring androgen, formed by irreversible 5Ξ±-reduction of Testosterone via the enzyme 5Ξ±-reductase. It binds the androgen receptor with 2-3Γ higher affinity than testosterone, exhibits slower dissociation kinetics, and cannot be aromatized to estradiol, making it a pure androgenic signal that drives male sexual differentiation, prostate growth, hair follicle miniaturization, and metabolic anabolism.
Think of DHT as testosterone's "turbo-charged twin" that enters the cell and sits in the driver's seat with superglue. Regular testosterone can get pulled out of the seat (to become estrogen via aromatase), but DHT is stuck there β once it grabs the androgen receptor, it holds on 2-3 times tighter and stays bound much longer. It's like a key that not only fits the lock perfectly but also turns harder, producing more dramatic effects with each turn. In the prostate, this turbo-charged signal is like turning up the volume on a growth amplifier β great for development, disastrous when it stays on too long and the prostate swells like an overinflated balloon, squeezing the urethra shut. In hair follicles on the scalp, DHT is the shrink ray: it miniaturizes follicles year after year until they produce only peach fuzz. But in muscles and bones, DHT is the foreman shouting "BUILD!" β driving protein synthesis and strength. Because DHT can't be converted to estrogen (the aromatase enzyme doesn't recognize it), it skews the androgen-to-estrogen balance hard toward the masculine side β all accelerator, no brakes.
Synthesis:
- Testosterone β 5Ξ±-reductase (Type 1 in liver/skin; Type 2 in prostate/genital skin/hair follicles) β DHT
- 5Ξ±-reductase uses NADPH as cofactor to reduce the Ξ4,5 double bond in testosterone's A-ring
- DHT production is tissue-specific: highest in prostate, genital skin, scalp hair follicles, liver
Receptor Binding and Genomic Signaling:
- DHT diffuses into target cells
- Binds to cytoplasmic androgen receptor (AR) with ~2.5Γ higher affinity than testosterone (Kd ~0.25 nM vs ~0.65 nM)
- DHT-AR complex undergoes conformational change β dissociation from heat shock proteins (HSP90, HSP70)
- Dimerization of DHT-AR complexes
- Nuclear translocation via nuclear localization signals
- Binding to androgen response elements (AREs) on DNA
- Recruitment of coactivators (SRC-1, SRC-2, CBP/p300)
- Enhanced transcription of androgen-responsive genes:
- IGF-1 (insulin-like growth factor-1) β cell proliferation
- EGF (epidermal growth factor) β epithelial growth
- FGF21 (fibroblast growth factor) β stromal expansion
- PSA (prostate-specific antigen) β prostate function
- Myosin heavy chain β muscle contraction
- Creatine kinase β energy metabolism
Non-Genomic Signaling:
- Membrane-bound AR activation β AKT pathway β protein synthesis
- PI3K/Akt β mTORC1 β muscle hypertrophy
- MAPK/ERK pathway β cell survival and proliferation
Metabolic Fate:
- DHT is irreversible (cannot be converted back to testosterone)
- Cannot be aromatized to estradiol (lacks Ξ4,5 double bond required by aromatase)
- Metabolized to 3Ξ±-androstanediol and 3Ξ²-androstanediol by 3Ξ±/Ξ²-hydroxysteroid dehydrogenases
- Conjugated with glucuronic acid or sulfate β urinary excretion
graph TD
T[Testosterone] -->|"5Ξ±-reductase Type 2"| DHT[DHT]
T -->|aromatase| E2[Estradiol]
DHT -->|X Cannot be aromatized| E2
DHT --> AR[Androgen Receptor cytoplasm]
AR --> HSP["AR + HSP90/HSP70 complex"]
HSP -->|DHT binding| CONF[Conformational change]
CONF --> DIM[AR-DHT dimer]
DIM --> NUC[Nuclear translocation]
NUC --> DNA[Binding to AREs]
DNA --> COA[Coactivator recruitment]
COA --> TRANS[Gene transcription]
TRANS --> IGF["IGF-1 β"]
TRANS --> EGF_OUT["EGF β"]
TRANS --> PSA["PSA β"]
TRANS --> MYO["Myosin β"]
IGF --> PROLIF[Cell proliferation]
EGF_OUT --> EPIT[Epithelial growth]
PSA --> PROST[Prostate function]
MYO --> MUSC[Muscle contraction]
DHT --> MEMB[Membrane AR]
MEMB --> PI3K[PI3K/Akt]
PI3K --> MTOR[mTORC1]
MTOR --> HYPER[Muscle hypertrophy]
Benign Prostatic Hyperplasia (BPH):
- DHT accumulation in prostate drives uncontrolled stromal and epithelial hyperplasia via sustained IGF-1 and EGF upregulation
- Prostate enlargement β urethral compression β urinary retention, nocturia, incomplete bladder emptying
- 5Ξ±-reductase inhibitors (finasteride 5 mg/day blocks Type 2; dutasteride 0.5 mg/day blocks Type 1+2) reduce prostate volume by ~25% over 6-12 months
- Risk: persistent sexual dysfunction (post-finasteride syndrome) in ~2-4% of men, even after discontinuation
- Mechanism of sexual side effects: DHT depletion β reduced neurosteroid Allopregnanolone β altered GABAergic tone in brain
Androgenic Alopecia (Male Pattern Baldness):
- DHT miniaturizes scalp hair follicles (vertex/frontal regions) via prolonged anagen shortening and follicle downsizing
- Androgen sensitivity determined by androgen receptor CAG repeat polymorphisms (fewer repeats = higher sensitivity)
- Finasteride 1 mg/day reduces scalp DHT by ~60-70%, stabilizes hair loss in ~80% of men
- Paradox: DHT promotes beard/body hair growth but inhibits scalp hair β tissue-specific coactivator expression
Metabolic and Anabolic Effects:
- DHT enhances muscle protein synthesis via mTORC1 activation independent of IGF-1
- Supports bone mineralization through osteoblast proliferation
- DHT deficiency (from 5Ξ±-reductase inhibition) linked to increased insulin resistance, reduced muscle mass, elevated HbA1c
- Selfish System Connection: DHT prioritizes reproductive fitness (muscle, libido) over long-term metabolic health β classic Antagonistic pleiotropy
Prostate Cancer:
- DHT may accelerate existing prostate cancer via AR-driven proliferation pathways
- Androgen deprivation therapy (ADT) targets this mechanism but causes severe metabolic side effects (sarcopenia, osteoporosis, insulin resistance)
- Paradox: low testosterone/DHT also associated with higher-grade prostate cancers (mechanism unclear)
Evolutionary Mismatch:
Intervention Implications:
- BPH/hair loss: 5Ξ±-reductase inhibitors, but monitor for metabolic/sexual side effects
- Support DHT balance: resistance training, zinc (5Ξ±-reductase cofactor regulation), saw-palmetto (mild 5Ξ±-reductase inhibition), manage chronic inflammation
- Avoid: chronic stress (elevates cortisol β suppresses testosterone β compensatory 5Ξ±-reductase upregulation)
- DHT binds androgen receptor with Kd ~0.25 nM (vs testosterone Kd ~0.65 nM) β 2.5Γ higher affinity
- Serum DHT is typically 10% of testosterone levels (~50 ng/dL vs ~500 ng/dL in adult males)
- DHT has 3Γ slower dissociation rate from AR compared to testosterone β more sustained genomic effects
- 5Ξ±-reductase Type 2 is the dominant isoform in prostate, genital skin, and hair follicles
- Finasteride reduces serum DHT by ~70%, intraprostatic DHT by ~85-90%
- DHT cannot be aromatized to estradiol (lacks Ξ4,5 double bond) β pure androgenic signal
- Post-finasteride syndrome affects ~2-4% of users with persistent sexual dysfunction, depression, cognitive fog
- DHT drives prostate volume increase at rate of ~1-2% per year after age 50 in untreated men
- Scalp DHT concentrations in androgenic alopecia are 2-3Γ higher than in non-balding scalp
- DHT upregulates IGF-1 by 30-50% in prostate stromal cells within 48 hours of exposure
- 5Ξ±-reductase inhibitors reduce prostate cancer detection by ~25%, but increase high-grade tumors detected by ~25% (controversial)
- DHT levels peak at age 20-30, then decline ~1-2% per year (slower decline than testosterone)
- Testosterone β immediate precursor hormone; DHT is the irreversible, non-aromatizable metabolite with 2-3Γ higher AR affinity
- 5Ξ±-reductase β enzyme catalyzing testosterone β DHT conversion; Type 2 isoform dominant in prostate/genital tissues
- androgen receptor β nuclear receptor bound by DHT with exceptional affinity and slow dissociation kinetics
- aromatase β cannot metabolize DHT (unlike testosterone) β DHT shifts androgen:estrogen ratio toward pure androgenic signaling
- estradiol β testosterone can convert to estradiol; DHT cannot, altering hormonal balance in tissues with high 5Ξ±-reductase activity
- DHEA β upstream precursor in steroidogenesis pathway leading through androstenedione β testosterone β DHT
- Allopregnanolone β neurosteroid synthesized from progesterone; reduced when DHT synthesis is inhibited, contributing to post-finasteride neuropsychiatric effects
- IGF-1 β DHT upregulates IGF-1 expression in prostate stromal/epithelial cells, driving cell proliferation and BPH
- EGF β epidermal growth factor upregulated by DHT in prostate, contributing to epithelial hyperplasia
- mTORC1 β activated via DHT β PI3K/Akt pathway in muscle tissue, driving protein synthesis and hypertrophy
- libido β DHT essential for male sexual desire; deficiency (from 5Ξ±-reductase inhibition) causes persistent libido loss in subset of men
- muscle hypertrophy β DHT activates satellite cell proliferation and myofibrillar protein synthesis independent of testosterone
- Osteoblasts β DHT stimulates osteoblast proliferation and bone formation, contributing to male skeletal strength
- insulin resistance β chronic DHT suppression (5Ξ±-reductase inhibition) associated with worsened glucose metabolism and increased fat mass
- Acne β DHT drives sebaceous gland activity; high DHT in adolescence/young adulthood linked to acne severity
- Cortisol β chronic stress-induced hypercortisolemia suppresses testosterone but may upregulate 5Ξ±-reductase as compensatory mechanism
- zinc β cofactor for 5Ξ±-reductase; zinc deficiency reduces DHT synthesis; excess zinc may inhibit enzyme activity
- saw-palmetto β herbal 5Ξ±-reductase inhibitor with weaker effect than finasteride (~25-30% DHT reduction)
- chronic inflammation β inflammatory cytokines (IL-6, TNF-Ξ±) upregulate 5Ξ±-reductase expression in adipose tissue, increasing local DHT production
- Prostate cancer β DHT may accelerate prostate cancer progression via AR-mediated cell cycle promotion, though relationship is complex
- Osteoporosis β DHT deficiency (from androgen deprivation therapy or 5Ξ±-reductase inhibition) accelerates bone loss in men
- sarcopenia β DHT loss contributes to age-related muscle wasting; supplementation in hypogonadal men increases lean mass